IP Library Patent Application 11743411
Patent Application
App. No. 11/743,411

FENTANYL SUSPENSION-BASED SILICONE ADHESIVE FORMULATIONS AND DEVICES FOR TRANSDERMAL DELIVERY OF FENTANYL

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/743,411
Abstract

Silicone adhesive formulations are provided, in which fentanyl particles are suspended one or more a solvated silicone adhesives. The formulations can be used for manufacturing improved, matrix-type transdermal devices for administering fentanyl.

Claims (22)

1 . A transdermal or transmucosal dosage form comprising:

a matrix; and

a drug; wherein the total amount of said drug present in said dosage form exceeds the solubility limit of said drug in said matrix.

2 . A dosage form according to aspect 1 , wherein said drug is dispersed in said matrix at a concentration greater than the solubility limit of the drug in the matrix.

3 . A dosage form according to aspect 2 , wherein said drug is substantially uniformly dispersed in said matrix.

4 . A dosage form according to aspect 1 , wherein said drug and said matrix are present as substantially discrete layers.

5 . A dosage form according to aspect 1 , wherein said dosage form further comprises a pressure sensitive adhesive layer on one surface of said dosage form.

6 . A dosage form according to aspect 1 , wherein said dosage form further comprises a backing layer on one surface of said dosage form.

7 . A dosage form according to aspect 1 , wherein said dosage form further comprises a pressure sensitive adhesive layer on one surface of said dosage form and a backing layer on an opposing surface of said dosage form.

8 . A dosage form according to aspect 7 , wherein said pressure sensitive adhesive layer comprises a mucoadhesive.

9 . A dosage form according to aspect 1 , wherein said dosage form further comprises a pressure sensitive adhesive layer on one surface of said dosage form and a release liner in contact with said pressure sensitive adhesive layer.

10 . A method for preparing a transdermal or transmucosal dosage form comprising a matrix and a drug dispersed in the matrix, wherein the total amount of the drug present in the dosage form exceeds the solubility limit of the drug in the matrix, said method comprising:

sequentially forming two or more layers of drug and two or more layers of matrix such that the amount of drug contained in the two or more layers of drug exceeds the solubility limit of the drug in the matrix.

11 . A method according to aspect 10 , wherein, subsequent to said forming, the drug becomes dispersed in the matrix.

12 . A method according to aspect 10 , wherein, subsequent to said forming, the drug becomes substantially uniformly dispersed in the matrix.

13 . A method according to aspect 10 , wherein, subsequent to said forming, said drug and said matrix remain as substantially discrete layers.

14 . A method according to aspect 10 , wherein the drug layers and the matrix layers are sequentially formed over a substrate.

15 . A method according to aspect 14 , wherein the substrate is a backing layer.

16 . A method according to aspect 15 , wherein said method further comprises:

forming a pressure sensitive adhesive layer over the drug layers and the matrix layers.

17 . A method according to aspect 14 , wherein the substrate is a pressure sensitive adhesive layer.

18 . A method according to aspect 17 , wherein said method further comprises: forming a backing layer over the drug layers and the matrix layers.

Assignments (6)
PATENT RELEASE Recorded Dec 10, 2012
From: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
To: DEY PHARMA L.P. (F/K/A DEY, L.P.); MYLAN PHARMACEUTICALS, INC.; MYLAN BERTEK PHARMACEUTICALS INC.; MYLAN TECHNOLOGIES, INC.; SOMERSET PHARMACEUTICALS, INC.; MYLAN INSTITUTIONAL INC. (F/K/A UDL LABORATORIES, INC.); MYLAN INC.
Reel/Frame 029440/0967 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 12, 2011
From: MILLER, KENNETH J., II; GOVIL, SHARAD K.; BHATIA, KULJIT SINGH
To: MYLAN PHARMACEUTICALS INC.
Reel/Frame 027368/0650 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 10, 2011
From: MILLER, KENNETH J., II; GOVIL, SHARAD K.; BHATIA, KULJIT SINGH
To: MYLAN PHARMACEUTICALS, INC.
Reel/Frame 027368/0754 →
SECURITY AGREEMENT Recorded Nov 21, 2011
From: MYLAN PHARMACEUTICALS, INC.; MYLAN BERTEK PHARMACEUTICALS INC.; MYLAN TECHNOLOGIES, INC.; MYLAN INSTITUTIONAL INC. (F/K/A UDL LABORATORIES, INC.); SOMERSET PHARMACEUTICALS, INC.; DEY PHARMA, L.P. (F/K/A DEY L.P.)
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 027270/0799 →
RELEASE OF SECURITY INTEREST Recorded Nov 18, 2011
From: JPMORGAN CHASE BANK, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
To: MYLAN TECHNOLOGIES, INC.; DEY, INC. (F/K/A DEY LABORATORIES, INC.); MYLAN BERTEK PHARMACEUTICALS INC.; MYLAN PHARMACEUTICALS, INC.; DEY PHARMA, L.P. (F/K/A DEY L.P.); MYLAN INSTITUTION INC. (F/K/A UDL LABORATORIES, INC.); MYLAN INC. (F/K/A MYLAN LABORATORIES INC.)
Reel/Frame 027261/0928 →
SECURITY AGREEMENT Recorded Oct 24, 2007
From: MYLAN LABORATORIES INC.; DEY, L.P.; DEY, INC.; MYLAN PHARMACEUTICALS, INC.; MYLAN TECHNOLOGIES, INC.; MYLAN BERTEK PHARMACEUTICALS INC.; UDL LABORATORIES, INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 020004/0404 →